Fosamax (Alendronate) Medicare Advantage Coverage: How to Get It Covered and Save

How Medicare Advantage Plans Cover Alendronate

Most Medicare Advantage plans that include prescription drug benefits (known as MA-PD plans) place generic alendronate on Tier 1 of their formulary, the preferred generic tier. This means alendronate receives the lowest possible copay. Plans sold by UnitedHealthcare, Humana, Aetna, Cigna, and Blue Cross Blue Shield affiliates all list generic alendronate on their 2026 formularies without prior authorization or step therapy requirements for the standard 70 mg weekly tablet 1.

The reason for universal coverage is straightforward. Alendronate is the oldest oral bisphosphonate on the market, with an FDA approval date of October 1995 and generic availability since 2008. Multiple manufacturers produce it, which keeps costs low for insurers. The Centers for Medicare & Medicaid Services (CMS) requires all Part D plans to cover drugs in certain protected classes, and while bisphosphonates are not in a protected class, their clinical necessity for fracture prevention in older adults means plans include them voluntarily 2.

Dr. Ethel Siris, a leading osteoporosis researcher at Columbia University, has noted: "Alendronate remains the most prescribed osteoporosis medication worldwide because it is effective, well-studied, and now extremely affordable as a generic." That affordability makes it a natural fit for Medicare Advantage formularies.

What You Will Pay Out of Pocket

Your actual copay depends on three variables: your plan's tier structure, the pharmacy you use, and where you fall in the Part D coverage phases. Most MA-PD enrollees pay between $0 and $4 for a 30-day supply of alendronate 70 mg at a preferred pharmacy during the initial coverage phase 3.

Here is a breakdown by coverage phase in 2026:

Deductible phase. Some MA-PD plans waive the Part D deductible for Tier 1 generics entirely. If your plan does not waive the deductible, you pay the full negotiated price (typically $4 to $15) until you meet the annual deductible of $645 in 2026.

Initial coverage phase. After meeting any deductible, you pay your plan's Tier 1 copay. For preferred generics at preferred pharmacies, this is often $0 to $4.

Coverage gap (donut hole). Since the Inflation Reduction Act's Part D redesign took effect in 2025, Medicare enrollees pay no more than $2,000 in total out-of-pocket drug costs annually. Alendronate's low cost means it contributes very little toward that cap 4.

Catastrophic phase. Once you reach the $2,000 cap, your cost drops to $0 for the rest of the year.

A 2023 analysis published in the Journal of Bone and Mineral Research found that among Medicare Part D enrollees filling bisphosphonate prescriptions, 78% paid less than $10 per fill for generic alendronate, and 41% paid $0 5.

Brand-Name Fosamax vs. Generic Alendronate

Brand-name Fosamax is significantly more expensive than its generic equivalent. The average cash price for brand Fosamax 70 mg sits near $500 for a 30-day supply. Generic alendronate costs roughly $15 at retail pharmacies without insurance.

Medicare Advantage plans almost always require generic substitution when a generic is available. If your prescriber writes for "Fosamax" specifically, the pharmacy will dispense generic alendronate unless the prescription states "dispense as written" (DAW). Requesting brand-name Fosamax when a generic exists will push you to a higher formulary tier (Tier 3 or non-preferred brand), raising your copay to $40 to $95 per month on most plans.

The FDA considers generic alendronate therapeutically equivalent to Fosamax (rated "AB" in the Orange Book), meaning it contains the same active ingredient in the same dose and has demonstrated bioequivalence in pharmacokinetic studies 6. There is no clinical reason to pay more for the brand. The Fracture Intervention Trial (FIT), which enrolled 6,459 postmenopausal women with low bone density, demonstrated that alendronate reduced hip fracture risk by 47% (RR 0.53, 95% CI 0.31 to 0.91) over three years compared to placebo 7. These results apply equally to generic formulations.

How to Find the Lowest Price on Alendronate

Even though alendronate is already cheap, several strategies can reduce your cost to $0.

Use your plan's preferred pharmacy. MA-PD plans negotiate lower prices at preferred pharmacies. Walmart, Costco, and several grocery store chains appear on preferred pharmacy lists for major plans. Your copay at a preferred pharmacy can be $0 compared to $3 to $10 at a non-preferred pharmacy for the same drug.

Use the Medicare Plan Finder. The CMS Plan Finder tool at medicare.gov lets you enter your specific medications and zip code to compare copays across every available MA-PD plan in your area. During the Annual Enrollment Period (October 15 through December 7), you can switch plans if a competitor offers better Tier 1 copays.

Ask about $0 generic programs. Some MA-PD plans offered by Humana, SCAN Health, and certain Blue Cross affiliates feature $0 copays on all Tier 1 generics at preferred pharmacies, including alendronate. These programs change year to year, so verify current availability through the Plan Finder 8.

Consider mail-order pharmacy. Most MA-PD plans offer a 90-day supply by mail for the same copay as a single 30-day fill at retail. For a drug you take long-term like alendronate, this reduces pharmacy trips and may save $8 to $20 annually.

Discount programs for cash pay. If you are in the deductible phase and want to avoid applying alendronate's small cost to your Part D spending, GoodRx and RxSaver coupons often bring generic alendronate below $4 at chains like Costco and Kroger. The Mark Cuban Cost Plus Drug Company sells alendronate 70 mg (4 tablets, a one-month supply) for $4.20 including markup and dispensing fee 9.

Prior Authorization and Step Therapy Requirements

Generic alendronate 70 mg weekly tablets almost never require prior authorization or step therapy under Medicare Advantage plans. This drug is the first-line treatment recommended by the American Association of Clinical Endocrinology (AACE) and the Endocrine Society for most patients with osteoporosis or high fracture risk 10.

The 2020 AACE/ACE Clinical Practice Guidelines state: "Alendronate, risedronate, or zoledronic acid are recommended as initial pharmacologic therapy for most patients at high fracture risk" 10. Because alendronate is the guideline-preferred starting agent, insurers have no basis to restrict access.

Exceptions exist for less commonly prescribed formulations. Alendronate oral solution (70 mg/75 mL) and the combination product Fosamax Plus D (alendronate 70 mg with cholecalciferol 2,800 IU or 5,600 IU) may require prior authorization or may not appear on every formulary. If you need the oral solution due to difficulty swallowing tablets, ask your prescriber to submit a prior authorization citing medical necessity. Approval rates for the oral solution exceed 85% when dysphagia or esophageal stricture is documented 11.

Comparing Alendronate Coverage to Other Osteoporosis Drugs

Alendronate has the best insurance coverage profile of any osteoporosis medication. The table below shows how MA-PD coverage compares across common options.

Alendronate (Fosamax generic): Tier 1, $0 to $4 copay, no prior authorization.

Risedronate (Actonel generic): Tier 1, $0 to $10 copay, no prior authorization. Slightly more expensive than alendronate at retail ($20 to $30 cash).

Ibandronate (Boniva generic): Tier 1 to 2, $3 to $15 copay, no prior authorization. Monthly dosing appeals to some patients.

Zoledronic acid (Reclast): Covered under Part B (infusion), not Part D. Administered once yearly in a clinic. 20% coinsurance after Part B deductible unless supplemental coverage applies 12.

Denosumab (Prolia): Covered under Part B (injection). Average cost before insurance: $1,800 per dose, given every 6 months. 20% coinsurance applies. Prior authorization sometimes required 13.

Romosozumab (Evenity): Covered under Part B. Average cost before insurance: $1,800 per monthly dose for 12 months. Prior authorization required by most plans.

Teriparatide (Forteo): Part D, Tier 5 (specialty). $100+ copay in most plans, though the $2,000 annual cap limits exposure 14.

For most Medicare Advantage enrollees with newly diagnosed osteoporosis, starting with alendronate makes financial and clinical sense. The FLEX trial extension showed that women who took alendronate for 5 years and then continued for 5 more years had a 55% lower risk of clinical vertebral fractures compared to those who switched to placebo (2.4% vs. 5.3%, P=0.002) 15.

What to Do If Your Plan Denies Coverage

Outright denial of generic alendronate coverage is rare but not impossible. If it happens, you have structured appeal rights under Medicare.

Step 1: Request a coverage determination. Call the number on your plan's member card and ask why alendronate was denied. Common reasons include formulary error, incorrect billing code, or the pharmacy submitting for the brand instead of generic.

Step 2: File a redetermination (Level 1 appeal). Your plan must respond within 7 days for a standard appeal or 72 hours for an expedited appeal. Include a letter from your prescriber stating the clinical indication (postmenopausal osteoporosis, steroid-induced osteoporosis, or osteopenia with high FRAX score).

Step 3: Escalate to the Independent Review Entity (IRE). If the plan upholds the denial, you can file with the IRE (Maximus Federal Services). The IRE reverses Part D denials in approximately 40% of cases 16.

While pursuing appeals, you can fill the prescription at cash price. At $4 to $15 per month, paying out of pocket for alendronate during the appeal process is feasible for most enrollees.

Timing Your Coverage: Enrollment Periods and Plan Selection

Choosing the right MA-PD plan can save money across all your medications, not just alendronate. Three enrollment windows matter.

Annual Enrollment Period (AEP): October 15 to December 7. This is the primary window to switch MA-PD plans. Use the Medicare Plan Finder to compare Tier 1 copays, preferred pharmacy networks, and premium costs.

Medicare Advantage Open Enrollment Period (MA OEP): January 1 to March 31. If you are already enrolled in a Medicare Advantage plan, you can switch to a different MA plan or return to Original Medicare with a standalone Part D plan.

Special Enrollment Periods (SEPs). You may qualify for an SEP if you move, lose other coverage, or qualify for Extra Help (Low-Income Subsidy). The Extra Help program covers most Part D costs for individuals with limited income, reducing alendronate copays to $0 in virtually every case 17.

If you qualify for Extra Help (annual income below $22,590 for individuals or $30,660 for couples in 2026, with limited assets), your generic copay drops to $0 to $4.50 regardless of plan tier structure.

Long-Term Considerations for Alendronate Coverage

Alendronate is typically prescribed for 3 to 5 years as initial therapy, after which your clinician may recommend a "bisphosphonate holiday" for patients at moderate fracture risk. The AACE 2020 guidelines recommend reassessing fracture risk after 5 years of oral bisphosphonate therapy and continuing treatment beyond 5 years only in patients who remain at high risk 10.

During a bisphosphonate holiday, no osteoporosis medication costs accrue. When restarting, generic alendronate coverage will still be available on your MA-PD formulary. Alendronate has the longest post-discontinuation efficacy data of any bisphosphonate: the FIT Long-term Extension (FLEX) showed that residual fracture reduction persisted for 5 years after stopping in women who had taken it for 5 years 15.

If you transition from alendronate to a Part B drug like denosumab or zoledronic acid, your cost structure changes. Part B drugs are subject to the Part B deductible ($257 in 2026) and 20% coinsurance, which can mean $300+ per year for denosumab unless you have Medigap or plan-specific supplemental benefits.

For the 90%+ of Medicare Advantage enrollees who start osteoporosis treatment, generic alendronate at $0 to $4 per month remains the most cost-effective option with the strongest long-term fracture-prevention data.